GeneDx (WGS) Competitors

GeneDx logo
$46.34 -4.68 (-9.16%)
As of 01:58 PM Eastern
This is a fair market value price provided by Massive. Learn more.

WGS vs. RDNT, LFST, BLLN, OPCH, and HIMS

Should you buy GeneDx stock or one of its competitors? GeneDx's main competitors and comparable companies include RadNet (RDNT), LifeStance Health Group (LFST), Billiontoone (BLLN), Option Care Health (OPCH), and Hims & Hers Health (HIMS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does GeneDx compare to RadNet?

GeneDx (NASDAQ:WGS) and RadNet (NASDAQ:RDNT) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

GeneDx has a beta of 2, meaning that its stock price is 100% more volatile than the broader market. Comparatively, RadNet has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market.

GeneDx currently has a consensus target price of $90.14, suggesting a potential upside of 76.68%. RadNet has a consensus target price of $89.67, suggesting a potential upside of 16.62%. Given GeneDx's higher possible upside, equities analysts plainly believe GeneDx is more favorable than RadNet.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GeneDx
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67
RadNet
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78

61.7% of GeneDx shares are held by institutional investors. Comparatively, 77.9% of RadNet shares are held by institutional investors. 25.2% of GeneDx shares are held by company insiders. Comparatively, 5.1% of RadNet shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, RadNet had 4 more articles in the media than GeneDx. MarketBeat recorded 18 mentions for RadNet and 14 mentions for GeneDx. RadNet's average media sentiment score of 0.73 beat GeneDx's score of 0.55 indicating that RadNet is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GeneDx
2 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
RadNet
6 Very Positive mention(s)
5 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

RadNet has higher revenue and earnings than GeneDx. RadNet is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GeneDx$427.54M3.56-$21.02M-$3.78N/A
RadNet$2.04B2.97-$18.65M-$0.29N/A

RadNet has a net margin of -0.94% compared to GeneDx's net margin of -24.10%. RadNet's return on equity of 3.14% beat GeneDx's return on equity.

Company Net Margins Return on Equity Return on Assets
GeneDx-24.10% 1.98% 1.02%
RadNet -0.94%3.14%1.08%

Summary

RadNet beats GeneDx on 12 of the 17 factors compared between the two stocks.

How does GeneDx compare to LifeStance Health Group?

GeneDx (NASDAQ:WGS) and LifeStance Health Group (NASDAQ:LFST) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

LifeStance Health Group has a net margin of 4.29% compared to GeneDx's net margin of -24.10%. LifeStance Health Group's return on equity of 4.82% beat GeneDx's return on equity.

Company Net Margins Return on Equity Return on Assets
GeneDx-24.10% 1.98% 1.02%
LifeStance Health Group 4.29%4.82%3.30%

61.7% of GeneDx shares are held by institutional investors. Comparatively, 85.5% of LifeStance Health Group shares are held by institutional investors. 25.2% of GeneDx shares are held by insiders. Comparatively, 3.5% of LifeStance Health Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

GeneDx presently has a consensus price target of $90.14, indicating a potential upside of 76.68%. LifeStance Health Group has a consensus price target of $14.86, indicating a potential upside of 2.60%. Given GeneDx's higher probable upside, equities analysts clearly believe GeneDx is more favorable than LifeStance Health Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GeneDx
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67
LifeStance Health Group
0 Sell rating(s)
4 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.70

In the previous week, GeneDx had 1 more articles in the media than LifeStance Health Group. MarketBeat recorded 14 mentions for GeneDx and 13 mentions for LifeStance Health Group. GeneDx's average media sentiment score of 0.55 beat LifeStance Health Group's score of 0.38 indicating that GeneDx is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GeneDx
2 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
LifeStance Health Group
5 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

LifeStance Health Group has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than LifeStance Health Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GeneDx$427.54M3.56-$21.02M-$3.78N/A
LifeStance Health Group$1.42B3.87$9.66M$0.1976.21

GeneDx has a beta of 2, meaning that its share price is 100% more volatile than the broader market. Comparatively, LifeStance Health Group has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

Summary

LifeStance Health Group beats GeneDx on 11 of the 17 factors compared between the two stocks.

How does GeneDx compare to Billiontoone?

GeneDx (NASDAQ:WGS) and Billiontoone (NASDAQ:BLLN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

In the previous week, GeneDx had 6 more articles in the media than Billiontoone. MarketBeat recorded 14 mentions for GeneDx and 8 mentions for Billiontoone. GeneDx's average media sentiment score of 0.55 beat Billiontoone's score of 0.33 indicating that GeneDx is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GeneDx
2 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Billiontoone
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

GeneDx currently has a consensus target price of $90.14, indicating a potential upside of 76.68%. Billiontoone has a consensus target price of $124.38, indicating a potential upside of 29.14%. Given GeneDx's stronger consensus rating and higher possible upside, analysts plainly believe GeneDx is more favorable than Billiontoone.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GeneDx
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67
Billiontoone
1 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.55

Billiontoone has lower revenue, but higher earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GeneDx$427.54M3.56-$21.02M-$3.78N/A
Billiontoone$305.11M15.08$7.45M$0.92104.68

Billiontoone has a net margin of 10.95% compared to GeneDx's net margin of -24.10%. Billiontoone's return on equity of 9.16% beat GeneDx's return on equity.

Company Net Margins Return on Equity Return on Assets
GeneDx-24.10% 1.98% 1.02%
Billiontoone 10.95%9.16%6.78%

61.7% of GeneDx shares are owned by institutional investors. 25.2% of GeneDx shares are owned by insiders. Comparatively, 50.2% of Billiontoone shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Billiontoone beats GeneDx on 8 of the 14 factors compared between the two stocks.

How does GeneDx compare to Option Care Health?

GeneDx (NASDAQ:WGS) and Option Care Health (NASDAQ:OPCH) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

GeneDx currently has a consensus target price of $90.14, indicating a potential upside of 76.68%. Option Care Health has a consensus target price of $29.48, indicating a potential downside of 7.04%. Given GeneDx's stronger consensus rating and higher probable upside, equities research analysts clearly believe GeneDx is more favorable than Option Care Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GeneDx
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67
Option Care Health
0 Sell rating(s)
14 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.13

Option Care Health has a net margin of 3.74% compared to GeneDx's net margin of -24.10%. Option Care Health's return on equity of 19.06% beat GeneDx's return on equity.

Company Net Margins Return on Equity Return on Assets
GeneDx-24.10% 1.98% 1.02%
Option Care Health 3.74%19.06%7.32%

GeneDx has a beta of 2, suggesting that its stock price is 100% more volatile than the broader market. Comparatively, Option Care Health has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

In the previous week, GeneDx had 10 more articles in the media than Option Care Health. MarketBeat recorded 14 mentions for GeneDx and 4 mentions for Option Care Health. Option Care Health's average media sentiment score of 1.65 beat GeneDx's score of 0.55 indicating that Option Care Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GeneDx
2 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Option Care Health
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

61.7% of GeneDx shares are owned by institutional investors. Comparatively, 98.1% of Option Care Health shares are owned by institutional investors. 25.2% of GeneDx shares are owned by insiders. Comparatively, 1.7% of Option Care Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Option Care Health has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Option Care Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GeneDx$427.54M3.56-$21.02M-$3.78N/A
Option Care Health$5.65B0.84$207.59M$1.3922.81

Summary

Option Care Health beats GeneDx on 9 of the 16 factors compared between the two stocks.

How does GeneDx compare to Hims & Hers Health?

GeneDx (NASDAQ:WGS) and Hims & Hers Health (NYSE:HIMS) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

Hims & Hers Health has a net margin of -6.65% compared to GeneDx's net margin of -24.10%. GeneDx's return on equity of 1.98% beat Hims & Hers Health's return on equity.

Company Net Margins Return on Equity Return on Assets
GeneDx-24.10% 1.98% 1.02%
Hims & Hers Health -6.65%-9.62%-1.38%

61.7% of GeneDx shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 25.2% of GeneDx shares are held by insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

GeneDx has a beta of 2, meaning that its stock price is 100% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.53, meaning that its stock price is 153% more volatile than the broader market.

In the previous week, Hims & Hers Health had 38 more articles in the media than GeneDx. MarketBeat recorded 52 mentions for Hims & Hers Health and 14 mentions for GeneDx. GeneDx's average media sentiment score of 0.55 beat Hims & Hers Health's score of -0.29 indicating that GeneDx is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GeneDx
2 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Hims & Hers Health
1 Very Positive mention(s)
6 Positive mention(s)
17 Neutral mention(s)
21 Negative mention(s)
2 Very Negative mention(s)
Neutral

Hims & Hers Health has higher revenue and earnings than GeneDx. Hims & Hers Health is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GeneDx$427.54M3.56-$21.02M-$3.78N/A
Hims & Hers Health$2.35B1.84$128.37M-$0.83N/A

GeneDx presently has a consensus price target of $90.14, indicating a potential upside of 76.68%. Hims & Hers Health has a consensus price target of $31.53, indicating a potential upside of 70.11%. Given GeneDx's stronger consensus rating and higher probable upside, research analysts clearly believe GeneDx is more favorable than Hims & Hers Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GeneDx
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67
Hims & Hers Health
1 Sell rating(s)
12 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.13

Summary

GeneDx beats Hims & Hers Health on 9 of the 16 factors compared between the two stocks.

Get GeneDx News Delivered to You Automatically

Sign up to receive the latest news and ratings for WGS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

WGS vs. The Competition

MetricGeneDxHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.38B$10.66B$7.76B$11.63B
Dividend YieldN/A2.54%2.46%4.43%
P/E Ratio-12.2635.9934.2929.91
Price / Sales3.232.088.485.64
Price / Cash22.6323.3421.9322.50
Price / Book5.653.604.393.67
Net Income-$21.02M$332.46M$3.51B$392.03M
7 Day Performance-15.48%-3.67%-5.19%-3.98%
1 Month Performance-27.14%-1.36%-4.33%-6.46%
1 Year Performance-64.23%19.27%-1.33%-6.95%

GeneDx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
WGS
GeneDx
3.0007 of 5 stars
$46.35
-9.2%
$90.14
+94.5%
-60.2%$1.38B$427.54MN/A1,300
RDNT
RadNet
3.542 of 5 stars
$77.09
-1.1%
$90.43
+17.3%
+2.3%$6.07B$2.38BN/A11,264
LFST
LifeStance Health Group
3.015 of 5 stars
$14.51
+0.9%
$14.00
-3.5%
+126.3%$5.52B$1.68B76.4510,961
BLLN
Billiontoone
3.4668 of 5 stars
$107.74
-2.3%
$124.38
+15.4%
+7.0%$5.09B$305.11M117.23713
OPCH
Option Care Health
3.091 of 5 stars
$31.71
+0.0%
$29.48
-7.0%
+11.6%$4.75B$5.75B22.818,266

Related Companies and Tools


This page (NASDAQ:WGS) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners